Lesson focus: Immunosuppressants deliberately reduce harmful cellular, humoral or both immune responses. Their life-saving roles include prevention and treatment of transplant rejection and control of severe autoimmune/inflammatory disease. Their predictable cost is infection, malignancy, organ toxicity, cytopenia, reproductive risk and drug-interaction burden.
Clinical rule: Never prescribe an immunosuppressant as an isolated drug name. State the indication, target immune pathway, baseline infection screen, monitoring plan, interactions, pregnancy plan and red flags.
Learning objectives
Explain T-cell activation and the sites of action of immunosuppressants; classify individual drugs; compare calcineurin inhibitors, mTOR inhibitors, antiproliferatives, glucocorticoids and biologics; outline transplant induction, maintenance and rejection treatment; and recognise major adverse effects, interactions and monitoring needs.
1. Definition and major uses
Immunosuppressants inhibit cellular immunity, humoral immunity or both. They are used to prevent allograft rejection after kidney, liver, heart and other transplants; to treat acute rejection; and to control autoimmune or inflammatory disorders such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, psoriasis, uveitis, myasthenia gravis and some vasculitides. The precise drug choice varies by disease, severity, organ function, pregnancy potential, infections, local availability and specialist guideline.
Balance, not elimination: inadequate suppression risks graft rejection or uncontrolled immune disease; excessive suppression risks opportunistic infection, sepsis, cancer and toxicity. Combination treatment uses different pathways so that each component can often be given at a lower dose.
2. T-cell activation: the mechanism map
The supplied lecture correctly centres on helper-T-cell activation. An antigen-presenting cell (APC) displays peptide on MHC class II to the T-cell receptor/CD4 complex. Co-stimulatory signals are also required. T-cell receptor signalling activates phospholipase C, generating DAG and IP3. IP3 raises intracellular calcium; calcium-calmodulin activates calcineurin. Calcineurin dephosphorylates NFAT, allowing NFAT to enter the nucleus and promote IL-2 and other cytokine-gene transcription. IL-2 then drives T-cell proliferation.
| Site in immune response | Drug approach | Examples |
|---|---|---|
| Antigen presentation/cytokine production | Broad anti-inflammatory suppression | Glucocorticoids |
| Calcineurin → NFAT → IL-2 transcription | Calcineurin inhibition | Cyclosporine, tacrolimus |
| IL-2 receptor growth signalling | mTOR inhibition or IL-2R blockade | Sirolimus/everolimus; basiliximab |
| Purine/pyrimidine synthesis and DNA replication | Antiproliferative therapy | Azathioprine, mycophenolate, methotrexate |
| TNF, IL-1, lymphocyte surface targets | Biological targeted suppression/depletion | Anti-TNF agents, anakinra, ATG, anti-CD antibodies |
3. Classification
Calcineurin inhibitors
Cyclosporine; tacrolimus.
mTOR inhibitors
Sirolimus; everolimus.
Antiproliferatives
Azathioprine; mycophenolate; methotrexate.
Glucocorticoids
Prednisolone; methylprednisolone and others.
Biological agents
Anti-TNF, IL-1 blockade, IL-2R antibodies, T-cell-depleting globulins and other monoclonal antibodies.
13. Practical monitoring by drug class
| Class | Before starting | During treatment | Do not miss |
|---|---|---|---|
| Calcineurin inhibitor | Renal function, BP, electrolytes, glucose, interaction review | Trough level, creatinine/eGFR, K+, Mg2+, BP, glucose | Nephrotoxicity, neurotoxicity, hyperkalaemia, interacting antimicrobials |
| mTOR inhibitor | CBC, lipids, wound status, renal/liver assessment | Drug level, CBC, lipids, urine protein, lung symptoms | Cytopenia, dyslipidaemia, poor wound healing, pneumonitis |
| Azathioprine | CBC, liver tests, TPMT/NUDT15 where available, allopurinol/febuxostat review | CBC and liver tests regularly | Marrow suppression, pancreatitis, infection |
| Mycophenolate | CBC, renal/liver tests, pregnancy plan | CBC, diarrhoea, infection, pregnancy prevention | Severe infection, leucopenia, embryo-fetal toxicity |
| Methotrexate | CBC, renal/liver tests, pregnancy assessment, alcohol/lung history | CBC, LFTs, creatinine, mouth/lung symptoms | Weekly dosing, pneumonitis, marrow/liver toxicity |
| Biologic | TB/hepatitis screen, CBC/LFTs, vaccination review | Infection surveillance and disease-specific tests | Reactivation of latent infection; avoid live vaccine where contraindicated |
14. Special situations
Pregnancy and conception
Every immunosuppressant requires a deliberate pregnancy discussion. Mycophenolate and methotrexate have substantial embryo-fetal risk and demand specialist-directed contraception and pre-conception switching. Azathioprine, tacrolimus and corticosteroids may sometimes be used in pregnancy for a compelling indication, but that is a specialist risk-benefit decision—not an invitation to self-continue or self-stop. Uncontrolled transplant rejection or autoimmune disease can itself endanger parent and fetus.
Infection and vaccination
Do not wait for a patient to become septic before considering infection prevention. Check vaccine history before planned long-term suppression, use inactivated vaccines appropriately, and avoid live vaccines during major immunosuppression unless specialist advice says otherwise. Fever, weight loss, persistent cough, dysuria, diarrhoea, shingles-like rash, oral ulcers or unexplained bruising require prompt review. In Uganda and other high-TB-burden settings, TB evaluation before anti-TNF therapy is a practical safety requirement.
Adherence and access
For transplant recipients, missed doses can cause graft rejection; doubled doses can cause toxicity. Patients should keep an updated medicine list, use one pharmacy where possible, report stock interruptions early and contact the transplant/medical team before taking herbal remedies, antibiotics, antifungals, anticonvulsants or NSAIDs. A “normal” single lab result does not exclude rejection or infection—interpret symptoms, levels, trends and graft-specific findings together.
15. Final summary
Immunosuppressants work at defined stages of immune activation: calcineurin inhibitors prevent IL-2 transcription; mTOR inhibitors block IL-2-driven proliferation; antiproliferatives limit lymphocyte expansion; corticosteroids broadly suppress inflammatory transcription; and biological agents block cytokines or deplete/disable lymphocytes. The same mechanisms that protect a graft or control autoimmunity create predictable risks. Safe practice combines the right regimen, screening, therapeutic monitoring, interaction control, reproductive planning and rapid response to infection or toxicity.
4. Calcineurin inhibitors
4.1 Cyclosporine
Cyclosporine is a cyclic polypeptide that enters T cells and binds the immunophilin cyclophilin. The cyclosporine-cyclophilin complex inhibits calcineurin, preventing NFAT activation, reducing IL-2 transcription and suppressing T-cell proliferation. The lecture’s G0/G1 arrest teaching point is useful: calcineurin inhibitors predominantly block early T-cell activation rather than directly destroying lymphocytes.
Uses: transplant prophylaxis and selected autoimmune disease. Modern disease-specific indications differ; do not use an old list alone. Adverse effects: nephrotoxicity, hypertension, hyperkalaemia, neurotoxicity/tremor, hyperuricaemia, dyslipidaemia, gingival hyperplasia, hirsutism, diabetes risk, infection and malignancy. Monitor blood pressure, renal function, electrolytes, glucose/lipids and trough drug levels where required.
4.2 Tacrolimus
Tacrolimus is chemically distinct but has the same final calcineurin target. It binds FKBP rather than cyclophilin; the tacrolimus-FKBP complex inhibits calcineurin. It is more potent by weight than cyclosporine, but that does not make it automatically “better”—drug selection and target trough range are transplant-program decisions.
Compare with cyclosporine: both cause nephrotoxicity, hypertension, neurotoxicity, hyperkalaemia, infection and malignancy. Tacrolimus commonly causes tremor and diabetes; cyclosporine more characteristically causes hirsutism and gingival hyperplasia. Both have highly important CYP3A/P-glycoprotein interactions and need therapeutic drug monitoring.
Interaction trap: macrolides such as erythromycin/clarithromycin, azole antifungals, grapefruit products and other CYP3A inhibitors can raise calcineurin-inhibitor levels and toxicity. Rifampicin, certain anticonvulsants and other enzyme inducers can lower levels and risk rejection. Additive nephrotoxicity occurs with aminoglycosides, amphotericin B, vancomycin, NSAIDs and other nephrotoxins. Always check interactions before adding medicines.
5. mTOR inhibitors: sirolimus and everolimus
Sirolimus (rapamycin) binds FKBP, but unlike tacrolimus its complex inhibits mTOR, a kinase needed for IL-2-driven cell-cycle progression, proliferation and differentiation. Thus tacrolimus and sirolimus share FKBP but act at different points. Sirolimus is not a calcineurin inhibitor and is not intrinsically nephrotoxic in the same way, although combinations and overall patient care can still harm renal function.
Uses: prevention/treatment of selected graft rejection, usually in combination regimens; everolimus/sirolimus also have specialised transplant and oncology-related roles. Drug-eluting coronary stents use limus drugs locally to limit smooth-muscle proliferation; this is not the same as systemic transplant dosing.
Adverse effects: hyperlipidaemia, thrombocytopenia, leucopenia, anaemia, mouth ulcers, diarrhoea, oedema, hypertension, impaired wound healing, proteinuria, pneumonitis and infection. Monitor lipids, full blood count, renal/liver parameters, urine protein and drug levels according to the regimen. Avoid assuming that sirolimus is a simple substitute during peri-operative wound healing.
6. Antiproliferative drugs
6.1 Azathioprine
Azathioprine is a prodrug of 6-mercaptopurine. Active metabolites interfere with de-novo purine synthesis and DNA replication, reducing the proliferation and function of activated lymphocytes. It predominantly depresses cell-mediated immunity. It is used in transplantation and selected autoimmune disorders including inflammatory bowel disease, rheumatoid arthritis, severe psoriasis and myasthenia gravis where appropriate.
Major safety: dose-related bone-marrow suppression, infection, hepatotoxicity, pancreatitis, gastrointestinal effects and malignancy risk with long-term immunosuppression. TPMT and/or NUDT15 testing or phenotype-guided dosing is important where available because reduced enzyme activity can cause profound myelotoxicity. Monitor full blood count and liver tests. Allopurinol or febuxostat can dangerously increase thiopurine exposure; doses must never be combined casually.
6.2 Mycophenolate mofetil/mycophenolic acid
Mycophenolate inhibits inosine-monophosphate dehydrogenase, reducing guanosine nucleotide synthesis. Activated T and B lymphocytes depend heavily on this pathway, making mycophenolate a central antiproliferative component of many transplant regimens and a specialist treatment in several immune-mediated diseases.
Adverse effects: diarrhoea, nausea, leucopenia, anaemia, infection, lymphoma/skin-cancer risk and severe embryo-fetal toxicity. Pregnancy prevention and pregnancy planning are essential; it is not a routine pregnancy-safe immunosuppressant. Monitor full blood count, renal/liver function, infection and adherence. Antacids and some binding agents can affect absorption; check the exact product.
6.3 Methotrexate
Methotrexate is a folate antagonist; at low weekly doses it is widely used as an immunomodulatory disease-modifying drug for rheumatoid arthritis, psoriasis and other selected autoimmune diseases. It reduces inflammatory cytokine signalling and cellular immunity. The lecture’s “first-line in many autoimmune diseases” point must be qualified: it is first-line for some conditions, not all, and must be used only within disease-specific protocols.
Safety: myelosuppression, hepatotoxicity, mucositis, pneumonitis, teratogenicity and serious toxicity if taken daily instead of weekly for inflammatory disease. Check dose frequency carefully; monitor full blood count, liver function, renal function and pregnancy status. Folate supplementation and interaction review are part of safe care.
7. Glucocorticoids
Glucocorticoids have broad anti-inflammatory and immunosuppressive actions. They reduce cytokine-gene expression, adhesion-molecule expression, antigen presentation/MHC expression and T-cell activation. They are used in transplant induction/maintenance and, at high doses, in many acute rejection episodes. Their broad action makes them effective but toxic.
Major adverse effects: infection, hyperglycaemia/diabetes, hypertension, fluid retention, osteoporosis, myopathy, mood/psychosis, cataract/glaucoma, peptic complications, skin changes and adrenal suppression. Use the minimum effective dose, monitor blood pressure/glucose/bone health and never stop long-term therapy abruptly without a taper plan.
8. Biological and antibody-based immunosuppression
| Target/agent | Mechanism and role | Key safety point |
|---|---|---|
| Anti-TNF agents (e.g. infliximab, adalimumab, etanercept) | Reduce TNF-driven inflammation in autoimmune disease | Screen for TB and hepatitis B; serious infection/reactivation risk |
| Anakinra | Recombinant IL-1 receptor antagonist | Infection and neutropenia risk; disease-specific use |
| Basiliximab | Anti-CD25 (IL-2 receptor alpha) antibody used in selected transplant induction | Blocks activated T-cell IL-2 signalling; protocol-based use |
| ATG (rabbit/equine anti-thymocyte globulin) | Polyclonal antibodies that deplete/modulate T cells | Infusion reactions, cytokine release, cytopenia, infection |
| Muromonab-CD3 | Historic murine anti-CD3 antibody | Withdrawn/discontinued in many settings because of severe cytokine-release toxicity; know historically, do not present as routine current therapy |
Anti-TNF agents can reactivate latent tuberculosis and hepatitis B; this is especially important in high-TB-burden settings. Before starting a biologic, screen for active/latent TB and hepatitis B according to local guidance, update appropriate non-live vaccines, investigate active infection and establish baseline full blood count/liver tests. Do not give live vaccines during significant immunosuppression unless a specialist confirms safety.
9. Immunosuppression in organ transplantation
Transplant treatment is usually described as induction, maintenance and anti-rejection/rescue therapy. Regimens are organ-specific and patient-specific; this framework is more durable than memorising one fixed triple-drug formula.
| Phase | Purpose | Typical approach |
|---|---|---|
| Induction | Prevent early high-risk rejection around transplantation | High-intensity peri-operative therapy, often antibody induction plus calcineurin inhibitor, corticosteroid and antiproliferative strategy |
| Maintenance | Long-term prevention of rejection with lowest sustainable toxicity | Usually multi-drug regimen: calcineurin inhibitor ± mTOR inhibitor, corticosteroid and mycophenolate/azathioprine; therapeutic drug monitoring |
| Acute rejection treatment | Suppress confirmed or strongly suspected rejection | Biopsy/clinical assessment where appropriate; high-dose corticosteroids are common first-line; resistant cases may need ATG or other specialist rescue |
The lecture mentions pulse methylprednisolone and older rescue use of muromonab-CD3. In current practice, the exact rejection pathway depends on organ, histology, donor-specific antibodies, infection and centre protocol. A transplant recipient with fever, falling urine output, jaundice, graft pain, new breathlessness or poor adherence requires urgent transplant-team assessment—not unsupervised dose changes.
10. Universal safety checklist
- Confirm diagnosis and indication; exclude uncontrolled infection before escalation.
- Record baseline full blood count, renal/liver function, blood pressure, glucose/lipids and relevant disease measures.
- Screen for TB, hepatitis B/C, HIV or other infections when indicated by the drug and setting.
- Assess pregnancy potential and contraception; methotrexate and mycophenolate have major embryo-fetal risks.
- Review every medicine, herbal preparation and grapefruit/food interaction where relevant.
- Plan therapeutic drug monitoring for calcineurin/mTOR inhibitors; trough level only has meaning when timing is correct.
- Counsel on fever, cough, dysuria, mouth ulcers, unusual bruising/bleeding, skin lesions and neurologic symptoms.
- Arrange age-appropriate cancer/skin surveillance and vaccination review; avoid live vaccines during significant suppression unless specifically advised.
11. Clinical cases
Case 1: Tacrolimus and new tremor
A renal-transplant patient starts clarithromycin and develops tremor with rising creatinine. Suspect raised tacrolimus exposure from CYP3A inhibition plus nephrotoxicity. Check urgent drug level/renal function and contact the transplant team; do not simply stop the transplant drug without specialist advice.
Case 2: Anti-TNF before screening
A patient with inflammatory arthritis is planned for adalimumab. They need infection assessment, TB and hepatitis-B screening according to local guidance and counselling on infection symptoms. Starting therapy in unrecognised active TB can be dangerous.
Case 3: Methotrexate daily error
A patient takes weekly methotrexate daily because the label was misunderstood and develops mouth ulcers and fever. This is a medical emergency: stop further doses and obtain urgent specialist/toxicology management with blood-count and organ-function assessment.
12. High-yield recall
- Cyclosporine + cyclophilin → calcineurin inhibition → reduced NFAT/IL-2 transcription.
- Tacrolimus + FKBP → calcineurin inhibition; same final pathway, different binding protein.
- Sirolimus + FKBP → mTOR inhibition → reduced IL-2 response/proliferation.
- Azathioprine → purine synthesis/DNA impairment; check TPMT/NUDT15 where possible and monitor marrow.
- Mycophenolate → IMPDH inhibition; major infection, cytopenia and pregnancy risk.
- Methotrexate is usually weekly for inflammatory disease, never a daily self-directed medicine.
- TNF inhibitors require TB/hepatitis-B awareness.
- All major immunosuppression increases infection and malignancy risk.
